The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma
December 27th 2023Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.
Read More
ICYMI: Highlights From EHA 2023
December 26th 2023The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.
Read More
Older, Younger Patients With MM Show Similar Outcomes With Teclistamab
December 20th 2023Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.
Read More
Top 5 Most-Read Multiple Myeloma Articles of 2023
December 19th 2023Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.
Read More
Patients With Multiple Myeloma Lack Awareness of CAR T-Cell Therapy, Research Says
December 15th 2023The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.
Read More
Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers
December 8th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says
November 22nd 2023A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.
Read More
CAR T-Cell Therapy Responses Differ by Race and Ethnicity, Study Finds
November 2nd 2023While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Read More
Study Identifies Mechanisms of Resistance to Immunotherapy for Multiple Myeloma
October 30th 2023Investigators found that myeloma cells may lose or change targets and subsequently go undetected by these therapies, suggesting that screening for such changes regularly could help guide treatment.
Read More
Ixazomib Shows Efficacy, Tolerability in Real-World R/R Multiple Myeloma Treatment
October 28th 2023A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.
Read More
Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features
October 27th 2023Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Read More
Intensive Therapy More Effective vs Less Intense Therapy in Frail Patients With MM
October 20th 2023A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.
Read More
Physical Activity Improves Performance, Frailty Scores, PROs in Multiple Myeloma
September 28th 2023Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores and patient-reported outcomes (PROs) in patients with multiple myeloma receiving systemic treatment.
Read More
Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis
September 20th 2023In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
Read More